Department of Biological Sciences and Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, United States of America.
PLoS Negl Trop Dis. 2021 Oct 13;15(10):e0009385. doi: 10.1371/journal.pntd.0009385. eCollection 2021 Oct.
Japanese encephalitis virus (JEV) is a major cause of neurological disability in Asia and causes thousands of severe encephalitis cases and deaths each year. Although Japanese encephalitis (JE) is a WHO reportable disease, cases and deaths are significantly underreported and the true burden of the disease is not well understood in most endemic countries. Here, we first conducted a spatial analysis of the risk factors associated with JE to identify the areas suitable for sustained JEV transmission and the size of the population living in at-risk areas. We then estimated the force of infection (FOI) for JE-endemic countries from age-specific incidence data. Estimates of the susceptible population size and the current FOI were then used to estimate the JE burden from 2010 to 2019, as well as the impact of vaccination. Overall, 1,543.1 million (range: 1,292.6-2,019.9 million) people were estimated to live in areas suitable for endemic JEV transmission, which represents only 37.7% (range: 31.6-53.5%) of the over four billion people living in countries with endemic JEV transmission. Based on the baseline number of people at risk of infection, there were an estimated 56,847 (95% CI: 18,003-184,525) JE cases and 20,642 (95% CI: 2,252-77,204) deaths in 2019. Estimated incidence declined from 81,258 (95% CI: 25,437-273,640) cases and 29,520 (95% CI: 3,334-112,498) deaths in 2010, largely due to increases in vaccination coverage which have prevented an estimated 314,793 (95% CI: 94,566-1,049,645) cases and 114,946 (95% CI: 11,421-431,224) deaths over the past decade. India had the largest estimated JE burden in 2019, followed by Bangladesh and China. From 2010-2019, we estimate that vaccination had the largest absolute impact in China, with 204,734 (95% CI: 74,419-664,871) cases and 74,893 (95% CI: 8,989-286,239) deaths prevented, while Taiwan (91.2%) and Malaysia (80.1%) had the largest percent reductions in JE burden due to vaccination. Our estimates of the size of at-risk populations and current JE incidence highlight countries where increasing vaccination coverage could have the largest impact on reducing their JE burden.
日本脑炎病毒(JEV)是亚洲地区神经功能障碍的主要原因,每年导致数千例严重脑炎病例和死亡。尽管日本脑炎(JE)是世界卫生组织报告的疾病,但病例和死亡的报告严重不足,大多数流行国家对该病的实际负担并不了解。在这里,我们首先对与 JE 相关的风险因素进行了空间分析,以确定适合持续 JEV 传播的区域以及生活在高风险区域的人口规模。然后,我们根据年龄特异性发病率数据估计 JE 流行国家的感染力(FOI)。然后,使用估计的易感人群规模和当前的 FOI 来估计 2010 年至 2019 年的 JE 负担,以及疫苗接种的影响。总体而言,估计有 15.431 亿人(范围:12.926-20.199 亿人)生活在适合地方性 JEV 传播的地区,这仅占生活在有地方性 JEV 传播的国家的 40 多亿人中的 37.7%(范围:31.6-53.5%)。根据基线感染风险人数,估计 2019 年有 56847 例(95%CI:18003-184525)JE 病例和 20642 例(95%CI:2252-77204)死亡。估计发病率从 2010 年的 81258 例(95%CI:25437-273640)和 29520 例(95%CI:3334-112498)死亡下降,主要是由于疫苗接种覆盖率的增加,这估计预防了 314793 例(95%CI:94566-1049645)和 114946 例(95%CI:11421-431224)死亡病例过去十年。印度是 2019 年 JE 负担最大的国家,其次是孟加拉国和中国。从 2010 年到 2019 年,我们估计疫苗接种在中国的绝对影响最大,预防了 204734 例(95%CI:74419-664871)和 74893 例(95%CI:8989-286239)死亡,而台湾(91.2%)和马来西亚(80.1%)由于疫苗接种,JE 负担的百分比降幅最大。我们对易感人群规模和当前 JE 发病率的估计突出了那些增加疫苗接种覆盖率可能对降低 JE 负担产生最大影响的国家。